Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2023 Feb 21:14:1081069.
doi: 10.3389/fendo.2023.1081069. eCollection 2023.

Serum anti-Müllerian hormone levels are associated with perinatal outcomes in women undergoing IVF/ICSI: A multicenter retrospective cohort study

Affiliations
Multicenter Study

Serum anti-Müllerian hormone levels are associated with perinatal outcomes in women undergoing IVF/ICSI: A multicenter retrospective cohort study

Yi-Chen He et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: Anti-Müllerian hormone (AMH) level has long been considered as a serum biomarker of ovarian reserve clinically, while emerging data suggest that serum AMH level may also predict pregnancy outcomes. However, whether pregestational serum AMH levels are related to perinatal outcomes among women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles is unknown.

Objective: To explore the association between different AMH levels and perinatal outcomes in women with live births in IVF/ICSI.

Methods: This multicenter retrospective cohort study was conducted among three different provinces in China, from January 2014 to October 2019. A total of 13,763 IVF/ICSI cycles with 5657 live-delivery pregnant women and 6797 newborns were recruited. Participants were categorized into three groups according to the <25th (low), 25 to 75th (average), and >75th (high) percentile of serum AMH concentration. Perinatal outcomes were compared among groups. Subgroup analyses were conducted based on the number of live births.

Results: Among women with singleton deliveries, low and high AMH levels increased the risk of intrahepatic cholestasis of pregnancy (ICP) (aOR1 = 6.02, 95%CI: 2.10-17.22; aOR2 = 3.65, 95%CI:1.32-10.08) and decreased the risk of macrosomia (aOR1 = 0.65, 95%CI:0.48-0.89; aOR2 = 0.72, 95%CI:0.57-0.96), while low AMH reduced the risk of large for gestational age (LGA, aOR=0.74, 95%CI:0.59-0.93) and premature rupture of membrane (PROM, aOR=0.50, 95%CI:0.31-0.79)compared with the average AMH group. In women with multiple deliveries, high AMH levels increased the risks of gestational diabetes mellitus (GDM, aOR=2.40, 95%CI:1.48-3.91) and pregnancy-induced hypertension (PIH, aOR=2.26, 95%CI:1.20-4.22) compared with the average AMH group, while low AMH levels increased the risk of ICP (aOR=14.83, 95%CI:1.92-54.30). However, there was no evidence of differences in preterm birth, congenital anomaly, and other perinatal outcomes among the three groups in both singleton and multiple deliveries.

Conclusions: Abnormal AMH levels increased the risk of ICP regardless of the number of live births for women undergoing IVF/ICSI, while high AMH levels increased the risks of GDM and PIH in multiple deliveries. However, serum AMH levels were not associated with adverse neonatal outcomes in IVF/ICSI. The underlying mechanism warrants further investigation.

Keywords: anti-Müllerian hormone; gestational diabetes mellitus; in vitro fertilization; intracytoplasmic sperm injection; intrahepatic cholestasis of pregnancy; perinatal outcomes; pregnancy-induced hypertension.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of the study cohort.
Figure 2
Figure 2
Forest plot summary of logistic regression analysis for risks of pregnancy outcomes in ART pregnancies with (A) singleton and (B) multiple deliveries. OR, odd ration; CI, confidence interval; aOR, adjusted odds ratio. aaOR was adjusted maternal age, paternal age, race, residence, gravidity, parity, duration of infertility, primary infertility, causes of infertility, study center, controlled ovarian stimulation protocol, type of insemination, transfer cycle types, embryo types, number of embryos transferred. baOR was adjusted maternal age, paternal age, residence, gravidity, parity, primary infertility, causes of infertility, study center, controlled ovarian stimulation protocol, type of insemination, transfer cycle types, embryo types.
Figure 3
Figure 3
Forest plot summary of logistic regression analysis for risks of neonatal outcomes in ART pregnancies with (A) singleton and (B) multiple deliveries. OR, odds ration; CI, confidence interval; aOR, adjusted odds ration; SGA, small for gestational age; AGA, appropriate for gestational age; NICU, neonatal care unit. aaOR was adjusted for maternal age, paternal age, race, residence, gravidity, parity, duration of infertility, primary infertility, causes of infertility, study center, controlled ovarian stimulation protocol, type of insemination, transfer cycle types, embryo types, number of embryos transferred. baOR was adjusted maternal age, paternal age, residence, gravidity, parity, primary infertility, causes of infertility, study center, controlled ovarian stimulation protocol, type of insemination, transfer cycle types, embryo types.

Similar articles

Cited by

References

    1. Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. . The physiology and clinical utility of anti-mullerian hormone in women. Hum Reprod Update (2014) 20(3):370–85. doi: 10.1093/humupd/dmt062 - DOI - PubMed
    1. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. . Anti-mullerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod (2004) 10(2):77–83. doi: 10.1093/molehr/gah015 - DOI - PubMed
    1. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, et al. . Anti-müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology. (2002) 143(3):1076–84. doi: 10.1210/endo.143.3.8691 - DOI - PubMed
    1. van Houten EL, Themmen AP, Visser JA. Anti-mullerian hormone (AMH): regulator and marker of ovarian function. Ann Endocrinol (Paris) (2010) 71(3):191–7. doi: 10.1016/j.ando.2010.02.016 - DOI - PubMed
    1. Lew R. Natural history of ovarian function including assessment of ovarian reserve and premature ovarian failure. Best Pract Res Clin Obstet Gynaecol (2019) 55:2–13. doi: 10.1016/j.bpobgyn.2018.05.005 - DOI - PubMed

Publication types

Supplementary concepts

LinkOut - more resources